Slingshot members are tracking this event:

GlycoMimetics (GLYC) Announces Dosing of First Patient in Phase I Trial of GMI-1271 in Multiple Myeloma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 14, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Dosing Of First Patient, Phase I Trial, Gmi-1271, Multiple Myeloma